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Abstract Treatment of rat 3Y1 fibroblasts with vasopressin 
(AVP) results in a transient activation of MAP kinase as potent 
as with EGF and serum. An antagonist of vasopressin receptor 
V1, but not an antagonist of V2, inhibited the AVP-induced 
activation of MAP kinases, indicating that AVP activates MAP 
kinases through V1 receptor. Prolonged TPA treatment of cells 
resulted in partial MAP kinase activation, indicating the presence 
of PKC-independent pathway. The pathway was inhibited by 
wortmannin, an inhibitor of Pl3-kinase. The results suggest hat 
wortmannin-sensitive molecules uch as PI3-kinase, are involved 
in the V1 receptor-mediated activation of the MAP kinase path- 
way independent of TPA-sensitive PKC. 
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1. Introduction 
The antidiuretic hormone vasopressin (AVP) is a cyclic non- 
apeptide involved in the homeostasis of body fluid osmolarity 
and blood pressure [1]. In addition, AVP exerts a variety of 
physiological effects on a variety of tissues and cells. These 
include platelet aggregation, metabolic stimulation, and cell 
proliferation [1,2]. These actions are mediated through specific 
cell surface receptors that are pharmacologically divided into 
VI and V2 receptors. VI and V2 receptors belong to a family 
of seven transmembrane G-protein coupled receptors [3 5]. V2 
receptor is found in a limited numbers of tissues, such as kid- 
ney, while V1 receptor is found in many tissues and cells [6]. 
Thus, it seems that the action of AVP in a variety of ceils, as 
listed above, involves the stimulation of V1 receptor. Previous 
studies have shown that V2 receptor stimulates adenylate 
cyclase, while V1 receptor activates phospholipase C (PLC). 
resulting in the production of inositol-l,4,5-triphosphate (IP3)
and 1,2-diacylglycerol (DAG), mobilization of intracellular 
Ca 2÷, influx of extracellular Ca 2÷, and activation of protein 
kinase C (PKC) [7]. V1 receptor stimulation also causes the 
activation of phospholipase D (PLD) and phospholipase A,
(PLA2), which might be involved in the activation of PKC and 
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intracellular Ca 2+ mobilization, respectively [7]. In addition to 
these immediate changes in cellular metabolism, AVP, most 
likely through V1 receptor, stimulates cell growth responses 
that accompany the induction of protein phosphorylation a d 
gene expression[8]. However, the molecular mechanism leading 
to these effects remains to be explored. 
Mitogen-activated protein kinases (MAP kinases) are acti- 
vated in a wide variety of cells upon stimulation of tyrosine 
kinase-type growth factor receptors [9]. One role of activated 
MAP kinases appears to be the linkage of cytoplasmic signaling 
events to nuclear events including the induction of DNA syn- 
thesis [8]. In addition to tyrosine kinase-type growth factor 
receptors, receptors coupled to G-proteins, such as thrombin 
receptors and PAF receptors, activate MAP kinase [10]. Recent 
experiments based on the overexpression f fl~' subunits of 
G-protein in COS cells suggest that G-protein coupled recep- 
tors activate MAP kinases through the fly subunits of G-pro- 
tein [11,12]. Thus, the signaling events downstream of G-pro- 
tein coupled receptors, including those for AVP, should be 
reconsidered in light of novel signaling molecules including 
MAP kinases. 
In the present study, we show that AVP activates MAP 
kinases through V1 receptor in rat 3Y1 fibroblasts. This signal- 
ing involves a novel pathway that is independent of TPA-sensi- 
tive PKC and seems to be mediated through PI3-kinase. 
2. Experimental procedures 
2.1. Materk~ls 
AVP ([ArgS]-vasopressin) was obtained from Sigma Co.; DDAVP 
(desamino-[D-ArgS]-vasopressin) and wortmannin were obtained from 
Peninsula Laboratories, Seikagaku Co. (Tokyo, Japan). OPC-21268 
and OPC-31260 were obtained from Otsuka Pharmaceutical Co. (To- 
kushima, Japan). 
2.2. (_'ell culture and stimulation 
Rat embryonic fibroblast 3Y1 cells (provided by Dr. G. Kimura, 
Kyushu University) were maintained in Dulbecco's modified Eagle's 
medium (DMEM) containing 10% fetal calf serum (FCS) and incu- 
bated as previously described [13]. Cells were rendered quiescent by 
incubation i  DMEM containing 0.5% FCS for 48 h. Cells were then 
treated with a variety of agents and collected after two rapid washes 
in ice-cold phosphate-buffered saline. 
2,3. Mobili O, shift assay 
Cells were ruptured in lysis buffer by sonication as described previ- 
ously [14]. Cell lysates were adjusted for cell number and subjected to
electrophoresis on 10% SDS-polyacrylamide gels. Immunoblotting was 
performed on nitrocellulose membranes with detection by an ECL 
system from Amersham. The antibody used was an anti-rat MAP-K R2 
(ErkI-CT) polyclonal antibody from UBI. The density of the ERK2 
band was quantified by a densitometer. The ERK2 response is ex- 
pressed as (shift band/non-shift band+shift band) x 100 (%). 
0014-5793/95/$9.50 ~'; 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)01382-2 
394 N. Nishioka et al./FEBS Letters 377 (1995) 393 398 
2.4. In-gel kinase assay 
In-gel kinase assays were performed according to the method of 
Kawashima et al. with slight modification [15]. After electrophoresis. 
SDS was removed by washing the gel with 20% 2-propanol. After 
soaking in 6 M guanidine-HCl and 0.04% Tween 40-containing buffer. 
the gel was incubated at 22°C for 1 h with 10 ml of 40 mM HEPES (pH 
7.5) containing 2 mM dithiothretiol, 0.1 mM EGTA, 5 mM MgCI 2, and 
25 mM [7-32p]ATP (25/zCi) for the kinase assay. As a substrate, MBP 
(myelin basic protein) (0.5 mg/ml) was included in the separating el 
prior to polymerization of the acrylamide. The samples were loaded 
onto 12% polyacrylamide gels, and the transfer of [y-32P]phosphate o
MBP was visualized and quantified by a radio-image analyzer (Fuji 
Film BAS 2000). 
3. Results 
3.1. A VP activates MAP kinases in rat 3 Y1 fibroblasts 
During the course of experiments to identify extracellular 
signals that activate the transcription of a reporter gene driven 
by a TPA-response lement (TRE) in serum-starved rat 3Y1 
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Fig. 1. AVP induces transient activation of MAP kinases. Cells were treated with a variety of agents (10 ng/ml AVP, 3 ng/ml EGF, 10% FCS, 30 
ng/ml TPA) (A), with 10 ng/ml AVP tbr different imes (~15 min) or (B) at different AVP concentrations (0, 1, 3, 10, and 30 ng/ml) for 5 min (C). 
The results of in-gel kinase assays are shown. Values shown (arbitrary units) are the averages of two samples. 
N. Nishioka et al./FEBS Letters 377 ~'1995 ; 393 398 395 
fibroblasts, we identified AVP as a potent activator of a re- 
porter gene containing TRE (data not shown). This is consis- 
tent with previous findings that AVP stimulates the expression 
ofc-fos and c-jun in A7r5 cells[8], although the molecular events 
leading to the activation of gene expression remain to be clari- 
fied. In order to analyze immediate changes in the cells that 
might be involved in the activation of gene expression upon 
AVP stimulation, we next examined the effect of AVP on MAP 
kinase activation. Recent experiments on growth factor recep- 
tors suggest the involvement of MAP kinase in a variety of cell 
functions including ene expression mediated by SRE (serum 
response lement) [16]. 
Serum-starved cells were stimulated with AVP and MAP 
kinase activities were evaluated by two different procedures, 
one involving the detection of MBP kinase activity in situ on 
a gel after denaturation a d renaturation (in-gel kinase assay), 
and the other detecting the mobility shift of MAP kinases on 
polyacrylamide g ls visualized after Western blotting with anti- 
MAP kinase antibody. Fig. 1A shows a typical example of the 
in gel kinase assay of total cell extract, clearly indicating the 
appearance of these two bands, upper and lower, with MBP 
kinase activity only when cells were stimulated with agents 
known to activate ERK1 and ERK2. such as EGF, serum, and 
TPA. These two bands most likely correspond to 
phosphorylated/activated p44 °rk~ (ERK1) and p42 erk2 (ERK2), 
respectively, for the following reasons. First. immunoprecipita- 
tion of the cell extracts with an antibody directed against ERK1 
followed by an in gel kinase assay resulted in the appearance 
of only two bands with a higher intensity in the upper band 
(data not shown). Second, Western blotting of total extracts as 
well as immunoprecipitates using anti-MAP kinase antibody 
resulted in the appearance of the two bands whose mobilities 
were retarded upon cell stimulation (data not shown). The 
results clearly show that AVP activates both ERK1 and ERK2, 
and is as potent as EGF, serum or TPA. EGF is one of the most 
effective mitogens in 3YI cells [17]. All stimuli examined, in- 
cluding AVP, caused stronger activation of ERK2 than ERK1. 
MAP kinases are rapidly activated following stimulation of 
quiescent cells with AVE The activity peaked 6 min after stim- 
ulation, with a 9 to 13-fold increase, and returned to near-basal 
levels after 12 min (Fig. 1B). Fig. IC shows that MAP kinases 
are activated in an AVP-dose-dependent manner. The activity 
reached a maximal level at a dose of 10-30 ng/ml, suggesting 
that the effect of AVP is mediated through a specific receptor. 
3.2. A VP activates MAP kinases through V1 receptor 
In order to clarify which type of receptors are involved in 
MAP kinase activation in rat 3Y1 cells, we used a selective V1 
antagonist (OPC-21268), V2 antagonist (OPC-31260), and a 
selective V2 agonist, DDAVP (desamino-[o-Arga]-vasopressin). 
Pretreatment of 3Y1 cells with OPC-21268, the V1 antagonist, 
inhibited the mobility shift of ERK2 in response to AVP (Fig. 
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Fig. 2 The effects of receptor agonists and antagonists on AVP-induced activation of ER K2. Cells were pretreated with a V 1 antagonist (OPC-21268) 
at a variety of concentrations (10 -2 to 10 -5 M) or a V2 antagonist (OPC-31260) at a variety of concentrations (10 -9 to 10 -6 M) for 10 min before 
10 ng/ml AVP stimulation for 5 min (A). Cells were treated with AVP or DDAVP, a selective V2 agonist, at a variety of concentrations (0,1, 3, 10, 
30, and 100 ng/ml) for 5 min (B). The values hown indicate the percentage of the shifted bands of ERK2. 
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Fig. 3 The effects of prolonged TPA treatment and/or wortmannin on AVP induced-activation of MAP kinases. (A and B) A variety of pretreatments 
was performed on cells before AVP or TPA stimulation (- = no stimulation: V = 10 ng/ml AVP; T = 30 ng/ml TPA). Cells received no pretreatment, 
pretreatment with 100 ng/ml TPA tbr 1 day, pretreatment with 10-: M wortmannin, or pretreatment with 100 ng/ml TPA for 1 day in addition to 
pretreatment with 10 -: M wortmannin. (AI The values hown indicate the percentage of the shifted bands of ERK2. The averages of two samples 
are shown. (B) The results of in-gel kinase assay of ERK2 are shown. Values for non-pretreated cells before AVP stimulation were taken as 100%. 
All data represent the mean _+ standard eviation of three independent of experiments.(C) ells were pretreated with wortmannin at a variety of 
concentrations (10 '~ M to ll) -~ M).The results of in-gel kinase assay are shown. The values from wortmannin-untreated c lls were taken as 100%. 
Values shown are the averages of two samples. 
2A). The OPC-21268 concentration that produced 50% inhibi- 
tion of the ERK2-mobil ity shift (IC5,) was approximately 
3 x 10 -7 M. On the other hand. pretreatment of 3Y1 cells with 
OPC-31260, the V2 antagonist, caused no inhibition of the 
mobility shift of ERK2 in response to AVP (Fig. 2A). The ICs~ 
of OPC-21268 for the displacement of specific AVP binding is 
reported to be 4x  10 -~ M and >10 -~ M for VI and V2 recep- 
tors, respectively [18], and the 1C~, of OPC-31260 for the dis- 
placement of specific AVP binding is reported to be 1.2 x 10 ~' 
M and 1.4 x 10 s M for VI and V2 receptors, respectively [19]. 
Thus. our results suggest hat the activation of ERK2 is medi- 
ated through the VI receptor. 
To confirm this, we next examined the effect of a V2 agonist. 
DDAVE The EC50 of DDAVP for ERK2 activation was ap- 
proximately 6 x 10 s M (Fig. 2BI. Since the reported EC~. or" 
AVP for adenylate cyclase activity is 2 × 10 '~ M [4], our result, 
considered together with those obtained for the antagonists, 
clearly indicates that AVP-induced activation of ERK2 is medi- 
ated through VI receptor, not V2 receptor, in rat 3YI fibro- 
blasts. Similar results were also obtained for the activalion of 
ERKI  (data not shown). 
3.3. Both TPA-sensitive, PK(U~h'pendent and -independent 
pathways are invoh,ed in the A VP-induced activation o/ 
MAP kinases 
Previous reports provide evidence lot the activation of the 
PLC/PKC pathway downstream of the V1 receptor [7]. Thus. 
we next examined the effect of prolonged TPA treatment on 
AVP-induced MAP kinase activation. As previously reported, 
rat 3Y1 fibroblasts express at least three TPA-sensitive PKC 
species, PKCc~, PKC#, and PKCe, and prolonged TPA treat- 
ment of 3YI cells causes down-regulation of all three TPA- 
sensitive PKC species [17]. When cells were pretreated with 
TPA for 1 day, the activation of MAP kinases caused by AVP 
was partially inhibited (Fig. 3). This indicates that AVP acti- 
vates MAP kinases through at least two independent pathways, 
one involving TPA-sensitive PKC and the other not involving 
TPA-sensitive PKC. 
3.4. 141)rtmannin inhibits A I/P-induced MAP kinase activation 
For a long time, the prevalent hypothesis for the mechanism 
of G-protein mediated signal transduction was that the GTP- 
liganded ~ subunit activated effectors, while the f17 subunit was 
only a negative regulator [20]. However, the fly subunit has 
recently been shown to be a positive regulator of MAP kinase 
[11,12]. In addition, the #Y subunit may also activate PI3-kinase 
[21,22]. In order to examine whether PI3-kinase is required for 
the activation of MAP kinase in response to AVP in 3Y1 cells, 
cells were pretreated with wortmannin for 30 rain. Wortmannin 
is known to specifically inhibit PI3-kinase in vivo and in vitro 
at a concentration of 10 7 M [10,23,24]. Incubation of cells with 
wortmannin resulted in an inhibition of AVP-induced MAP 
kinase activation (Fig. 3A,B,C). The concentration of wort- 
mannin required for the inhibition (40 52%) of MAP kinases 
in response to AVP was 10 7 M (Fig. 3C). Since wortmannin 
had no inhibitory effect on the TPA-induced activation of MAP 
kinases, it does not affect any signaling components between 
PKC and MAP kinase (Fig. 3A,B). Thus, the effect of wort- 
mannin is specific to AVP stimulation. Moreover, MAP kinase 
activation independent of prolonged TPA-treatment was also 
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inhibited by wortmannin, and wortmannin-insensitive MAP 
kinase activation was inhibited by prolonged TPA-treatment 
(Fig. 3A,B). 
4. Discussion 
Previous reports presented evidence that AVE most likely 
through V I receptor, stimulates the production of diacylglyc- 
erol, a potent activator of PKC, in hepatocytes, A7r5 cells, and 
A10 cells [7]. The activation of PKC upon AVP stimulation has 
also been examined in terms of the phosphorylation of 
MARCKS, a PKC substrate [25,26]. Our results confirm the 
presence of the PKC/MAP kinase pathway in 3Y1 cells (Figs. 
1A and 3A,B), as reported for many other cell types. Further- 
more, our results indicate that the pathway involving PKC 
mediates the activation of MAP kinase through VI receptor. 
Our results also show that the signaling pathway from the V1 
receptor to MAP kinase activation i volves an additional path- 
way that is independent ofTPA-sensitive PKC. Prolonged TPA 
treatment ofcells eliminates TPA-sensitive PKC [17], and there 
are TPA-insensitive classes of PKC, atypical PKC( and PKC2, 
in 3Y1 cells [27]. However, whether these molecules are in- 
volved in the signaling pathway remains to be clarified. 
The effect of wortmannin on the Vl-receptor-mediated acti- 
vation of MAP kinases uggests the involvement of PI3-kinase 
in the signaling pathway between Vl-receptor and MAP ki- 
nases. Since wortmannin did not inhibit TPA-mediated MAP 
kinase activation (Fig. 3), the action of wortmannin does not 
involve the pathway from PKC to MAP kinase activation. 
Since MAP kinase activation, independent of prolonged TPA- 
treatment, was also inhibited by wortmannin, and since wort- 
mannin-insensitive MAP kinase activation was inhibited by 
prolonged TPA-treatment (Fig. 3), there are at least two major 
pathways from Vl-receptor to MAP kinases. One involves 
TPA-sensitive PKC, the other involves wortmannin-sensitive 
molecules uch as PI3-kinase. These two pathways overlap to 
some extent, since prolonged TPA treatment followed by wort- 
mannin treatment ofcells resulted in a partial decrease in MAP 
kinase activation (Fig. 3). The presence of the former pathway 
is consistent with previous experiments showing that the stimu- 
lation of V1 receptors activates PLA,. PLC, and PLD, resulting 
in the production of IP3, and DAG. the mobilization of Ca ~-+, 
and the activation of PKC [7], and that the stimulation of CHO 
cells overexpressing the V1 a receptor causes inositol phosphate 
production and Ca :+ mobilization [5]. However, the latter path- 
way is a novel pathway and may correspond to the recently 
identified signaling pathway involving ¢/y subunits of G-pro- 
teins and ras [21,22]. Recently, it was reported that the overex- 
pression of f ly  subunits of G-protein in COS cells activates 
MAP kinase [11,12]. Moreover, a constitutive active mutant of 
PI3-kinase activates MAP kinase [28]. There are reports how- 
ing the generation of PIP3, a product of Pl3-kinase, upon stim- 
ulation of G-protein coupled receptors uch as thrombin and 
PAF [29,30]. These results suggest lhat G-protein coupled re- 
ceptor is able to activate PI3-kinase. There are multiple related 
PI3-kinases in mammalian cells, and it appears that pl l()y. an 
isotype of Pl3-kinases, is activated by G-protein [31,32]. Fur- 
thermore, one of the events downstream of Pl3-kinase activa- 
tion might involve the activation of MAP kinases. Our present 
observations suggest hat V I receptor stimulation activates 
MAP kinases through anovel pathway that most likely involves 
Pl3-kinase. The signaling molecules involved in the pathway 
from PI3-kinase and MAP kinase remain to be clarified. At 
present, TPA-insensitive atypical PKC~" is an attractive candi- 
date for such a molecule, since it is known to be activated 
directly by PIP3, a product of PI3-kinase [33]. Some TPA- 
sensitive PKCs such as PKCe, have also been reported to be 
activated by PIP3 [34]. In support of this notion, the overexpres- 
sion of nPKCE (TPA-sensitive PKC) and also aPKC)t (TPA- 
insensitive PKC) in 3Y1 cells resulted in the enhanced expres- 
sion of a reporter gene containing a synthetic TRE in response 
to AVP (Nishioka et al., unpublished observation). These ob- 
servations raise the interesting possibility of the existence of a 
novel signaling pathway, in addition to the PLC/PKC pathway, 
downstream of the V1 receptor. Experiments to clarify these 
points are important for understanding the pleiotropic and 
long-term action of AVP through V1 receptor, which includes 
the regulation of gene xpression and cell proliferation i a wide 
variety of cells. 
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